- Nachrichtendetail
-
13.05.2024 07:39:16 - dpa-AFX: *REGENERON: FDA ACCEPTS FOR PRIORITY REVIEW SBLA FOR DUPIXENT FOR CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS
Copyright(c) 2024 RTTNews.com. All Rights Reserved
Copyright RTT News/dpa-AFX
Copyright RTT News/dpa-AFX
| Name | WKN | Börse | Kurs | Datum/Zeit | Diff. | Diff. % | Geld | Brief | Erster | Schluss | |
|---|---|---|---|---|---|---|---|---|---|---|---|
 |
SANOFI SA INHABER EO 2 | 920657 | Xetra | 87,690 | 19.06.24 17:35:31 | -0,840 | -0,95% | 0,000 | 0,000 | 87,890 | 88,530 |
|
Regeneron Pharmaceuticals | 881535 | NASDAQ | 1.039,110 | 18.06.24 23:10:58 | -6,260 | -0,60% | 1.010,000 | 1.046,000 | 1.046,500 | 1.039,110 |
